Evidence map›Paper›PMID 30793254›Full record

SynthesisDrugs2019

Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.

Simona Lattanzi, Francesco Brigo, Eugen Trinka, Fabrizio Vernieri, Tommaso Corradetti, Mauro Dobran, Mauro Silvestrini

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05142228 phase2terminatednot on this mapstarted 2022, after this paper: background citation

Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2022 to 2022Enrolled5ConditionsTrigeminal NeuropathyArmsErenumab-Aooe, Placebo
NCT05162027 phase2terminatednot on this mapstarted 2022, after this paper: background citation

Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2022 to 2023Enrolled5ConditionsTemporomandibular DisordersArmsErenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Simona LattanziNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy. alfierelattanzisimona@gmail.com.ORCID http://orcid.org/0000-0001-8748-0083
Francesco BrigoDepartment of Neuroscience, Biomedicine and Movement Science, University of Verona, Verona, Italy.
Eugen TrinkaDepartment of Neurology, Christian Doppler Klinik, Paracelsus Medical University, Salzburg, Austria.
Fabrizio VernieriNeurology Unit, Campus Bio-Medico University, Rome, Italy.
Tommaso CorradettiNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy.
Mauro DobranClinic of Neurosurgery, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
Mauro SilvestriniNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, 60020, Ancona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel therapeutic options with improved efficacy and safety profiles are needed for the prophylaxis of migraine. In recent years, the inhibition of calcitonin gene-related peptide (CGRP) signaling has attracted growing interest in the pharmacological research on migraine. Erenumab is the first fully human monoclonal antibody directed against the CGRP receptor to be approved for use in migraineurs.

objectiveTo evaluate the efficacy and safety of erenumab as preventive treatment in patients with migraine using meta-analytical techniques.

methodsRandomized, placebo-controlled, single- or double-blinded trials were identified through a systematic literature search (October week 4, 2018). Main outcomes included the changes from baseline in monthly migraine days (MMD) and monthly acute migraine-specific medication days (MSMD) at week 12, and the incidence of adverse events (AEs), severe AEs (SAEs) and treatment withdrawal due to AEs. Mean difference (MD) and risk ratio (RR) with 95% confidence intervals (95% CIs) were estimated.

resultsAcross the five included trials, erenumab given as a subcutaneous injection at a monthly dosage of 70 mg and 140 mg was associated with a significantly greater reduction in baseline MMD (70 mg: MD - 1.3, 95% CI - 1.7 to - 1.0, p < 0.001; 140 mg: MD - 1.9, 95% CI - 2.3 to - 1.4, p < 0.001) and MSMD (70 mg: MD - 1.0, 95% CI - 1.6 to - 0.4, p < 0.001; 140 mg: MD - 1.8, 95% CI - 2.5 to - 1.1, p < 0.001) than placebo. There were no differences in the occurrence of AEs, SAEs, and drug withdrawal due to AEs between the erenumab and placebo groups.

conclusionsErenumab is an efficacious and well tolerated preventive treatment in adult patients with episodic and chronic migraine.

Indexed as

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsHumansInjections, SubcutaneousMigraine DisordersRandomized Controlled Trials as TopicTreatment OutcomeAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor Antagonistserenumab

Identifiers

PMID30793254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.